ADARx Pharmaceuticals Secures $200M Series C Financing, Paving Path for Next-Gen RNA Therapeutics

San Diego, CA, August 9, 2023 (Business Wire) -- ADARx Pharmaceuticals, Inc., a clinical-stage biotech enterprise spearheading the advancement of next-generation RNA therapeutics, has announced the successful conclusion of a $200 million Series C funding round. This funding endeavor was jointly spearheaded by Bain Capital Life Sciences and TCGX, and further embraced by new investors including Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates Inc., Venrock Healthcare Capital Partners, and Vivo Capital.

Read full article here.